Abstracts from PQRI and HEDIS 2010 requirements; pharmacy measures included 14 PQA measures being tested for these diseases. Measures were reviewed to identify: 1) type (process/outcome) 2) constructs; and 3) data requirements (pharmacy, medical, laboratory). RESULTS: Forty-eight measures were included (13 HEDIS, 21 PQRI, 14 PQA). HEDIS and PQRI measures for diabetes and dyslipidemia emphasize outcomes (achievement of Hgb A1c and LDL goals) and % receiving recommended screenings, while PQA measures emphasize process (adherence as gaps in therapy and proportion of days covered), excessive doses of diabetes medications, and suboptimal treatment (% on diabetes prescription without an ACEI or ARB). HEDIS, PQRI, and PQA measures for asthma assess use of controller medications, though 1 PQA measure also assesses overuse of beta agonists. Differences in the types and constructs of measures suggest opportunities for alignment. A bi-level framework that employs reporting pharmacy measures among patients who have not met the physician measure may facilitate a team approach for diabetes and hypertension quality, though this would only be feasible for organizations holding both medical and pharmacy data. CONCLUSIONS: Medication quality measures are of increasing importance, yet available physician and pharmacy measures differ. Findings suggest that testing a bi-level framework for diabetes and hypertension pharmacy quality measurement would be worthwhile. OBJECTIVES: Authorized generics (AGs) are products manufactured by a patent holder but marketed by a subsidiary or a third party company. AGs might increase competition and reduce generic prices when launched during the 180-day exclusivity period of an independent generic(s) (IGs). AGs launched during IG exclusivity might also present a long-term disadvantage to consumers by delaying timely entry of generics. The objectives of this study were: 1) to determine the trend in market share of AGs during the first six months for drugs launched with a first-filer(s) 180-day exclusivity; 2) to determine the trend in market share of AGs for the first six months for drugs launched without first-filer(s) exclusivity. METHODS: Five drugs were selected as cases to assess the effect of AGs launched during the exclusivity of IGs on market share of the brand and generic products. Each product selected had three subcategories: a brand name drug, an AG and at least one IG on the market. The unit of analysis was the number of prescriptions dispensed, without regard to the dispensed quantity. RESULTS: At the end of the first year, market shares of AGs launched with the exclusivity of an IG in the cases of Zocor®, Proscar® and Norvasc® were 37%, 52% and 49%, respectively. Meanwhile, market shares of AGs launched without the exclusivity of an IG in the cases of Arava® and Ambien® were 21% and 14%, respectively. CONCLUSIONS: AGs launched during IG exclusivity dominated the market and had the largest market share when compared to any other single market participant for the case. AGs launched during IG exclusivity obtain a dominant market share position and in the long run might discourage IG companies from timely generic introductions. Policy limiting the entry of AGs during the exclusivity of IG exclusivity might prevent delayed generic entry. OBJECTIVES: The primary objective was to evaluate the knowledge of the drugstore consumers from Brasilia and workers of ANVISA, for the regulation of prices of medicines. The specific objectives were to assess the knowledge of the populations on PMC, different price of generic medicines, estimate monthly expenses of the two samples and a preliminary comparative analysis between the two samples.
costs, cash prices and reimbursement rates of a brand name drug Lipitol and a generic drug Lisinopril acquired from the survey. Key independent variables include individual pharmacy attributes and local market structure measures. RESULTS: Reimbursements varied substantially across pharmacies. For Lipitor, best reputation (β = 0.101), easiest accessibility (β = 0.067), pharmacy ownership concentration index (β = 0.104) and area per capita income (β = −0.165) are significant predictors of pharmacy bargaining power. For Lisinopril, only easiest access (β = 0.082) and per capita income (β = −0.068) are found to be significant. CONCLUSIONS: Pharmacies with the best reputation, easiest access and facing less competition in its market receive higher reimbursement rates for brand name drugs. An independent pharmacy with the best reputation and easiest access and with average dispensing volume would receive $167,688 more in reimbursement a year than a pharmacy that doesn't have the best reputation and easiest access. Our results suggest that the current third party contracting practice rewards pharmacies with favorable attributes with higher reimbursements. Our results also imply that a collective bargaining law for independent pharmacies is likely to benefit those pharmacies currently receiving below average reimbursement rates due to weaker market positions, and would have the potential effect of raising costs and removing incentives for pharmacies to maintain the attributes that are valuable to customers.
HEALTH CARE USE & POLICY STUDIES -Beyond Drug Interventions

PHP101 DIFFERENCES IN CLINICIAN REPORTED EASE OF USE BETWEEN 2 HEMOSTASIS TREATMENT METHODS: RESULTS FROM A RANDOMIZED CONTROLLED STUDY
Rupnow MF 1 , McCormack J 2 , Vernon M 2 , Batiller J 3 , Hammond J 4 1 Ethicon, Inc., Somerville, NJ, USA, 2 United BioSource Corporation, Bethesda, MD, USA, 3 Ethicon, Inc, Somerville, NJ, USA, 4 Ethicon, Inc, Somverville, NJ, USA OBJECTIVES: To evaluate treatment group differences in clinician reported ease of use between Fibrin Pad (FP) and Surgicel for hemostasis in subjects with mild or moderate bleeding using a novel survey tool. METHODS: The Ease of Use Questionnaire (EUQ) was used as part of a randomized, controlled, clinical study of FP versus Surgicel for intra-operative hemostasis. Subjects were randomized at 11 institutions with a 2:1 FP to Surgicel ratio. Additional subjects were enrolled in the non-randomized phase and treated with FP. Subjects were stratified according to bleeding severity. Up to the first three subjects completed the EUQ at each institution. The final sample was N = 20 FP and N = 8 Surgicel (randomized) and N = 2 FP (non-randomized). The EUQ is a 19-item instrument evaluating clinicians' perceptions and preferences for hemostasis products on five subscales (Ease of Use, Satisfaction with Product Properties and Efficiency, Confidence in Efficacy, Global Confidence, and Global Satisfaction). 1 Differences in ease of use between treatment groups were evaluated using five ANCOVA models where subscale scores were the dependent variables, treatment group was the independent variable, and severity of bleeding was controlled for as the covariate. RESULTS: Mean subscale scores for Confidence in Efficacy (FP = 4.70 vs. S = 3.50), Global Confidence (FP = 4.70 vs. S = 4.13) and Global Satisfaction (FP = 4.85 vs. S = 4.04) were significantly higher for the FP group as compared to the Surgicel group (all p < 0.05). Mean subscales scores for Ease of Use (FP = 4.82 vs. S = 4.66) and Satisfaction (FP = 4.71 vs. S = 4.34) were higher for the FP group, but non-significant. CONCLUSIONS: Physicians reported higher ease of use, satisfaction, and global confidence with FP for hemostasis in mild to moderate bleeding. Non-significant results in the Ease of Use and Satisfaction subscales likely resulted from small sample sizes. Future studies should evaluate ease of use in the full range of bleeding severities and larger sample sizes.
PHP102 ADVANCING THE EVIDENCE BASE FOR ORTHOTICS AND PROSTHETICS
Mohandas A, Thompson E, Goldfarb N Jefferson School of Population Health, Philadelphia, PA, USA OBJECTIVES: Limited information is currently available regarding outcomes related to orthotics and prosthetics (O&P). Rapidly emerging technologies in the O&P field have increased the need for comparative effectiveness studies examining clinical, humanistic, and economic outcomes. The objective of this project was to establish and pilot test a patient registry for outcomes assessment. METHODS: A web-based survey system combining input from both O&P providers and their patients was developed and pilot-tested among nine O&P clinics across the country. The providers entered data on patient demographics, functional status, and mobility, for consenting patients, and then the patients entered information regarding functional abilities, satisfaction, pain, quality of life and cost of care. RESULTS: A total of 43 patients participated in the pilot survey. Respondents were predominantly insured through Medicare (43%) and 68% were men. With regard to functional abilities, 19% of the consumers required help with at least one activity of daily living. The percent of consumers experiencing an improvement in their ability to perform activities such as exercise, walking, bathing and dressing independently, all after receiving their device ranged from 18% to 51 %. Consumers also reported improved mood (64.9%), high satisfaction with their device (81.1%) and their provider (100%), and improved confidence (73%) after using their device. Several patients reported problems with ability to pay the out-of-pocket costs for their device (12.5%) or to afford device repair costs (9%). CONCLUSIONS: Preliminary results suggest that collecting outcomes data on this population is feasible, and that patients are benefiting from their O&P devices, through improved functional ability and emotional status. The systematic collection of patient reported outcomes may help to demonstrate the comparative effectiveness and value of O&P devices, and ultimately inform health insurance coverage decisions.
PHP103 WHEN ARE DIAGNOSTIC LABORATORY TESTS COST-EFFECTIVE? A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES
Fang CH 1 , Otero HJ 1 , Greenberg D 2 , Neumann PJ 1 1 Tufts Medical Center, Boston, MA, USA, 2 Ben-Gurion University of the Negev, Beer-Sheva, Israel OBJECTIVES: Diagnostic laboratory tests may add critical information to guide treatment and improve patient outcomes, but payers have often questioned its value. We reviewed the methodology and results of published cost-utility analyses (CUAs) of laboratory tests through 2008. METHODS: We screened all papers related to laboratory diagnostic tests in the Tufts Medical Center Cost-effectiveness Analysis Registry (www.cearegistry.org) which contains detailed information on over 2,000 published CUAs from 1976 to 2008. In addition to the standard auditing process, we recorded information on the reported test accuracy and IVD cost. We also captured whether any account was taken for potential value (or harm) unrelated to treatment consequences such as the "reassurance value of testing" or additional anxiety produced by test information. RESULTS: We identified 141 published CUAs pertaining to diagnostic laboratory tests, which contained 433 separate incremental cost-effectiveness ratios (ICER). The number of publications has increased rapidly in recent years. The most common areas of clinical application were hematology/oncology (n = 42, 29.8%), and OB/GYN (n = 36, 25.5%). Approximately 63% (89/141) of studies addressed the accuracy of the test. Only 10% (14/141) mentioned test safety or associated risks. A small number (n = 13, 9.2%) of CUAs mentioned or considered the potential value or harm of testing unrelated to treatment consequences. Over 55% of the reported ICERs were either dominant (more QALYs for less cost), or below $50,000 per QALY gained (in $US 2008). CONCLUSIONS: The number of CUAs evaluating laboratory tests technologies has increased substantially with applications to diverse clinical areas. The vast majority of CUAs have not attempted to measure the potential value or harms of diagnostic testing unrelated to treatment.
PHP104 THE BUDGET IMPACT OF ORAL NUTRITIONAL SUPPLEMENTS IN THE COMMUNITY SETTING IN THE NETHERLANDS
Nuijten M 1 , Freyer K 2 1 Ars Accessus Medica/Erasmus University Rotterdam, Jisp, The Netherlands, 2 Nutricia Advanced Medical Nutrition, on behalf of the Dutch Industry Organisation of Children and Dietary Nutrition (VNFKD), Zoetermeer, The Netherlands OBJECTIVES: To assess the budget impact of introducing oral nutritional supplements (ONS), being a medical nutrition product, in elderly patients from the perspective of the society in The Netherlands in 2009. METHODS: A model was developed to calculate the budgetary impact of using ONS in patients who are eligible for ONS due to disease-related malnutrition (DRM). The analysis is based on the cohort of elderly patients (>65 years) in the community setting in The Netherlands in 2009. The budget impact of ONS was assessed using a linear decision analytic model reflecting cost functions related with DRM. The model allowed the assessment of the cost reductions resulting from improvement in DRM due to treatment with ONS. Clinical probabilities and resource utilization were based on clinical trials and published literature; cost data were from official price tariffs. RESULTS: The use of ONS leads to annual cost savings of 313.3 million (18.9%), when all eligible patients are treated. The additional costs of ONS (357.0 million) are more than balanced by a reduction on other health care costs (370.3 million). Sensitivity analyses were performed on all parameters, including duration of treatment with ONS and the proportion of DRM. These results showed that the use of ONS in all sensitivity analyses leads to cost savings. CONCLUSIONS: This budget impact analysis shows that the use of ONS in eligible elderly patients in the community setting leads to a positive impact on the national health care budget in The Netherlands.
PHP105 THE UTILIZATION OF PARENTERAL NUTRITION IN THE UNITED STATES
Liu FX 1 , Mercaldi K 2 , Turpin R 1 1 Baxter Healthcare Corporation, Deerfield, IL, USA, 2 United BioSource Corporation, Bethesda, MD, USA OBJECTIVES: Parenteral nutrition (PN) is used with patients when oral or enteral nutrition isn't possible or adequate. Compared to other therapeutic interventions, relatively little is known about the real-world use of PN, the characteristics of patients who receive it, or the incidence of adverse events. Our objective was to explore PN as it is currently utilized in the United States, using a large, nationally representative inpatient database. METHODS: We examined the Premier Perspective TM database for all inpatients who received any PN between 2005 and 2007. Inpatients admitted with any outcome of interest (i.e., bacterial infection, hepatic dysfunction, hypoglycemia, acute cholecystitis, and phlebitis) were excluded. Hospital (e.g., bed size, geographic location, urban/rural status), patient (e.g., age, sex, comorbidities, severity), and PN characteristics were analyzed. RESULTS: Of over 11 million inpatients in the database, 68,984 adult, 3,083 pediatric and 34,307 neonates received PN. The average age of the adult patients was 66. Whites had a disproportionally higher probability of receiving PN (73.1%) than any other ethnic group. 46.2% of PN adult patients received PN in hospitals with bed size of 250-499, followed by hospitals with bed size of 500-749 (31.5%), and hospitals with bed size 50-249 (20.3%). Among adult PN patients, 38.9% were diagnosed with a malignancy, followed by undernutrition 33.2%, renal failure 31.3%, diabetes 24.4%. peritonitis 9.0%, acute pancreatitis 8.4%, and cirrhosis 7.6%. Compared to neonates, the infection rates and bloodstream infection rates (BSI) of the adult population were much higher (infection, 49.0% vs. 10.7%; BSI 26.9% vs. 1.7%). Most patients were primarily diagnosed with intestinal or peritoneal adhesion with obstruction (ICD-9 560.81). The majority of PN adult patients used procedure of venous catheterization (ICD-9 38.93). CONCLUSIONS: Large retrospective databases provide us with extraordinary insights to understand the characteristics of this vulnerable population and the real-world use of PN.
PHP106 THE HEALTH ECONOMIC IMPACT OF ORAL NUTRITIONAL SUPPLEMENTS IN THE COMMUNITY SETTING IN THE NETHERLANDS
Freyer K 1 , Nuijten M 2 1 Nutricia Advanced Medical Nutrition, on behalf of the Dutch Industry Organisation of Children and Dietary Nutrition (VNFKD), Zoetermeer, The Netherlands, 2 Ars Accessus Medica/Erasmus University Rotterdam, Jisp, The Netherlands OBJECTIVES: To assess the health economic impact of oral nutritional supplements (ONS), being a medical nutrition product, in elderly patients from the perspective of the society in The Netherlands in 2009. METHODS: This health economic analysis is based on a comparison of the use of ONS versus "no ONS" in patients who are eligible for ONS due to disease-related malnutrition (DRM). The base case analysis is based on a comparison in elderly patients (>65 years) in the community setting. The costs of the two treatment strategies ONS versus "no ONS" were assessed using a linear decision analytic model reflecting costs related with DRM. The model structure allowed for differences in costs for ONS and other resource utilization. Clinical probabilities and resource utilization were based on clinical trials and published literature; cost data were from official price tariffs. RESULTS: The use of ONS reduces the total costs from 31353 to 31180, which corresponds with a 3173 (12.8%) cost savings per patient. The additional costs of ONS are more than balanced by a reduction on hospitalization costs. Sensitivity analyses were performed on all parameters, including the risk of hospitalization and improvement of DRM. These results showed that the use of ONS in all sensitivity analyses leads to cost savings. CONCLUSIONS: This health economic analysis shows that the use of ONS in elderly patients in the community setting is a cost-effective treatment in The Netherlands and is dominant over standard care without ONS: it leads to cost savings and a higher effectiveness.
PHP107 THE HEALTH ECONOMIC IMPACT OF ORAL NUTRITIONAL SUPPLEMENTS IN THE HOSPITAL SETTING IN GERMANY
Nuijten M 1 , Freyer K 2 1 Ars Accessus Medica/Erasmus University Rotterdam, Jisp, The Netherlands, 2 Nutricia Advanced Medical Nutrition, Zoetermeer, The Netherlands OBJECTIVES: To assess the health economic impact of oral nutritional supplements (ONS), being a medical nutrition product, in hospitalized patients from the society perspective in Germany in 2009. METHODS: This health economic analysis is based on a comparison of the use of ONS versus "no ONS" in hospitalized patients who are eligible for ONS due to disease-related malnutrition (DRM). The costs of the two treatment strategies ONS versus "no ONS" were assessed using a linear decision analytic model reflecting costs related with DRM. The model structure allowed for differences in costs for ONS and length of stay. Clinical probabilities and resource utilization were based on clinical trials and published literature; cost data were from official price tariffs. RESULTS: The use of ONS reduces the total costs from 34105 to 33967, which corresponds with a 3138 cost savings per patient. The additional costs of ONS are more than balanced by a reduction on hospitalization costs. Sensitivity analyses were performed on all parameters, including length of stay and improvement of DRM. These results showed that the use of ONS in all sensitivity analyses leads to cost savings. CONCLUSIONS: This health economic analysis shows that the use of ONS in patients in the hospital setting is a cost-effective treatment in Germany
